• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by BetterLife Pharma Inc.

    BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Fully Subscribed Private Placement Financing
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Intent to Complete Private Placement of Units
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Advances BETR-001 IND-enabling Studies
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Extension of Warrants
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Pharma to Host Investors Update Call on September 18, 2023
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Continues Progress on BETR-001 IND-Enabling Studies
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    BetterLife Announces Closing of Private Placement
    From BetterLife Pharma Inc.
    Via GlobeNewswire
    Tickers BETRF CSE:BETR
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.